GDF15 and myocardial infarction: The FRISC II study showed that GDF15 may improve risk stratification in NSTE-ACS patients [24] and demonstrated that elevated levels of GDF15 independently predicted risk of death or recurrent myocardial infarction in patients not treated with revascularization.